Hua Medicine-B (06132) Opens Flat on Hong Kong IPO Debut; Three Core Products Yet to Be Approved
Miles Bennett
Huajian Future-B (06132) listed on the HKEX at HK$81.8 per share and opened flat on its first trading day — the clinical-stage biotech has zero approved products, leaving investors to weigh the gap between cash burn and eventual revenue.
How did the stock perform on day one?
Opened at HK$81.8, unchanged from the IPO price; still at that level at time of writing, with turnover of roughly HK$389 million.
The IPO issued 13.6 million shares at 100 shares per lot, raising net proceeds of about HK$1.019 billion.
This means → the market neither bid the stock up nor dumped it — a "wait and see" stance, not bullish, not bearish.
What does this company actually do?
Founded in 2017, Huajian Future (華健未來) is a clinical-stage biotech — meaning its drugs are still in trials, none yet on the market.
The founding team focuses on three therapeutic areas: autoimmune diseases, metabolic diseases, and oncology.
The company built an end-to-end small-molecule drug development platform integrating computational modeling with lab-based design, screening, and clinical translation.
In plain terms = this is a company with a platform and a pipeline but no product it can sell yet.
Where do the three core drugs stand?
The three lead candidates are HJ787, HJ178, and HJ891 — all self-developed small molecules classified as NMPA Class 1 innovative drugs (novel structure, novel target — not generics).
The key fact: none of the three has been approved for commercial sale. The company has zero product revenue.
This means → all of the company's value rests on a single gate: whether these drugs clear clinical trials and win approval. Before that gate, revenue is zero; only after it can cash flow begin.
How should investors think about this stock?
For a clinical-stage biotech, advancing core products from trials to regulatory approval is the only milestone that determines long-term value.
A flat debut + zero product revenue + all three drugs still in trials — this reflects a market that prices pure cash-burn-stage biotechs very cautiously.
Put simply = buying this stock is essentially a bet on clinical outcomes for three drugs — the potential payoff is large, but so is the uncertainty.
Content is for reference only, not financial advice.